Empagliflozin in the Treatment of Heart Failure With Reduced Ejection Fraction in Addition to Background Therapies and Therapeutic Combinations (EMPEROR-Reduced): A Post-hoc Analysis of a Randomised, Double-blind Trial
Lancet Diabetes Endocrinol 2022;10:35–45 doi.org/10.1016/S2213-8587(21)00292-8
Patients were randomly assigned 1:1 to add on oral empagliflozin 10mg QD and placebo and continued their background therapy. Treatments for heart failure could be added, withdrawn, or modified during follow-up.